New AI-assisted development approach reduces costs and accelerates delivery timelines for modern JavaScript applications ...
Abstract: Deep learning-based synthetic aperture radar (SAR) target recognition often suffers from sparsely distributed training samples and rapid angular variations due to scattering scintillation.
Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion in its U.S. initial public offering, tapping into a resurgent biotech market ...
Generate:Biomedicines is hoping to raise up to $425 million via a Nasdaq IPO, with the proceeds needed to bankroll its lead antibody through respiratory disease trials. The Flagship Pioneering-founded ...
Generate Biomedicines Inc., a biotechnology firm using artificial intelligence in drug development, is seeking to raise as much as $425 millon in an initial public offering, as listing activity in the ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The Somerville company aims to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results